Prime Medicine (PRME) News Today $3.44 +0.01 (+0.29%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.48 +0.04 (+1.16%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Prime Medicine (NYSE:PRME) Stock Price Up 4.9% - Here's What HappenedAugust 27 at 1:20 PM | marketbeat.comT. Rowe Price Investment Management Inc. Has $8.25 Million Stake in Prime Medicine, Inc. $PRMEAugust 27 at 4:50 AM | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesAugust 26 at 8:00 AM | globenewswire.comAnalysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $8.92August 21, 2025 | americanbankingnews.comPositive Signs As Multiple Insiders Buy Prime Medicine StockAugust 20, 2025 | uk.finance.yahoo.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comAnalysts Set Expectations for Prime Medicine FY2025 EarningsAugust 16, 2025 | marketbeat.comQ3 EPS Estimates for Prime Medicine Cut by HC WainwrightAugust 16, 2025 | marketbeat.comChardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00August 10, 2025 | marketbeat.comPrime Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What HappenedAugust 6, 2025 | marketbeat.comPrime Medicine Holds Special Stockholder MeetingAugust 5, 2025 | tipranks.comPrime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying ActivityAugust 5, 2025 | marketbeat.comFriday’s Insider Trades: Key Buys and Sells in US Stocks RevealedAugust 4, 2025 | investing.comArch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) StockAugust 2, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 SharesAugust 2, 2025 | insidertrades.comPrime Medicine Halts Sales Agreement ProspectusAugust 1, 2025 | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1, 2025 | finance.yahoo.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesAugust 1, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Shares Gap Down - Here's WhyAugust 1, 2025 | marketbeat.comPrime Medicine stock falls after pricing public offeringAugust 1, 2025 | za.investing.comJonesTrading Maintains a Buy on Prime Medicine (PRME)August 1, 2025 | msn.comPrime Medicine (NYSE:PRME) Trading Up 6.9% - Here's WhyJuly 31, 2025 | marketbeat.comPrime Medicine Announces Pricing of Public OfferingJuly 30, 2025 | globenewswire.comPrime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial StatementsJuly 30, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 8.9% - Here's WhyJuly 30, 2025 | marketbeat.comPrime Medicine Announces Proposed Public Offering of Common StockJuly 30, 2025 | globenewswire.comARK Investment Management LLC Sells 2,055,061 Shares of Prime Medicine, Inc. (NYSE:PRME)July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Shares Sold by Nikko Asset Management Americas Inc.July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 24, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 23.3% - Here's WhyJuly 21, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 6.6% - Time to Sell?July 18, 2025 | marketbeat.comWedbush Has Positive Forecast for Prime Medicine Q2 EarningsJuly 18, 2025 | marketbeat.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushJuly 17, 2025 | marketbeat.comPrime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic AdvancementsJuly 17, 2025 | tipranks.comPrime Medicine Shares Drop After New Funding, Equity InvestmentJuly 16, 2025 | marketwatch.comPrime Medicine (NYSE:PRME) Sees Large Volume Increase - Here's WhyJuly 16, 2025 | marketbeat.comCystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing TherapyJuly 16, 2025 | businesswire.comPrime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisJuly 16, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Trading 7.4% Higher - Should You Buy?July 14, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Down 11.8% - Should You Sell?July 11, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Sees Strong Trading Volume - What's Next?July 9, 2025 | marketbeat.comPrime Medicine: Pressing Forward With Lead Liver Targeting IndicationsJuly 7, 2025 | seekingalpha.comPrime Medicine stock soars amid gene editing sector momentumJuly 7, 2025 | finance.yahoo.comPrime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market MomentumJuly 7, 2025 | tipranks.comStock Traders Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)July 7, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up - What's Next?July 7, 2025 | marketbeat.comPrime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD DataJuly 6, 2025 | msn.comSumitomo Mitsui Trust Group Inc. Sells 164,157 Shares of Prime Medicine, Inc. (NYSE:PRME)July 4, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 SharesJune 24, 2025 | insidertrades.com Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRME Media Mentions By Week PRME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.391.03▲Average Medical News Sentiment PRME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼33▲PRME Articles Average Week Get the Latest News and Ratings for PRME and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Prime Medicine and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Arcutis Biotherapeutics News Dyne Therapeutics News Vericel News Sarepta Therapeutics News Apogee Therapeutics News Beam Therapeutics News Twist Bioscience News Immunocore News Cidara Therapeutics News Aurinia Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access